Vascular Biogenics Ltd. (VBLT) Income Statement Analysis

See more : BlackRock TCP Capital Corp. (TCPC) Income Statement Analysis – Financial Results

Complete financial analysis of Vascular Biogenics Ltd. (VBLT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vascular Biogenics Ltd., a leading company in the Biotechnology industry within the Healthcare sector.

You may be interested

Vascular Biogenics Ltd. (VBLT)

Industry: Biotechnology

Sector: Healthcare

Website: https://www.vblrx.com

About Vascular Biogenics Ltd.

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	658.00K	768.00K	922.00K	562.00K	585.00K	13.86M	0.00	0.00	0.00	0.00	0.00
Cost of Revenue	104.00K	365.00K	394.00K	163.00K	235.00K	340.00K	0.00	0.00	0.00	0.00	0.00
Gross Profit	554.00K	403.00K	528.00K	399.00K	350.00K	13.52M	0.00	0.00	0.00	0.00	0.00
Gross Profit Ratio	84.19%	52.47%	57.27%	71.00%	59.83%	97.55%	0.00%	0.00%	0.00%	0.00%	0.00%
Research & Development	21.65M	22.70M	19.66M	15.47M	15.94M	17.77M	12.45M	11.20M	10.97M	13.51M	10.57M
General & Administrative	11.75M	7.70M	5.36M	4.83M	5.15M	5.80M	3.79M	3.64M	3.77M	2.41M	1.89M
Selling & Marketing	0.00	0.00	0.00	0.00	397.00K	562.00K	0.00	0.00	0.00	0.00	0.00
SG&A	11.75M	7.70M	5.36M	4.83M	5.55M	6.36M	3.79M	3.64M	3.77M	2.41M	1.89M
Other Expenses	0.00	0.00	0.00	115.00K	70.00K	0.00	42.00K	34.00K	33.00K	43.00K	12.00K
Operating Expenses	33.41M	30.40M	25.01M	20.41M	21.56M	24.18M	16.28M	14.87M	14.78M	15.96M	12.47M
Cost & Expenses	33.51M	30.76M	25.41M	20.58M	21.79M	24.52M	16.28M	14.87M	14.78M	15.96M	12.47M
Interest Income	634.00K	120.00K	363.00K	870.00K	908.00K	335.00K	263.00K	100.00K	15.00K	27.00K	236.00K
Interest Expense	85.00K	44.00K	105.00K	313.00K	0.00	0.00	0.00	117.00K	0.00	0.00	0.00
Depreciation & Amortization	1.69M	120.00K	1.56M	2.58M	1.16M	156.00K	130.00K	122.00K	135.00K	169.00K	197.00K
EBITDA	-31.16M	-29.88M	-22.93M	-17.43M	-19.93M	-10.71M	-16.17M	-14.65M	-14.35M	-16.00M	-12.29M
EBITDA Ratio	-4,735.71%	-3,890.10%	-2,486.55%	-3,101.42%	-3,406.67%	-77.24%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Income	-32.85M	-30.00M	-24.48M	-20.01M	-21.21M	-10.66M	-16.28M	-14.87M	-14.78M	-15.96M	-12.47M
Operating Income Ratio	-4,992.86%	-3,905.73%	-2,655.42%	-3,561.21%	-3,625.13%	-76.85%	0.00%	0.00%	0.00%	0.00%	0.00%
Total Other Income/Expenses	549.00K	76.00K	258.00K	557.00K	749.00K	517.00K	273.00K	-17.00K	-2.63M	-1.41M	244.00K
Income Before Tax	-32.30M	-29.92M	-24.23M	-19.46M	-20.46M	-10.14M	-16.00M	-14.89M	-17.41M	-17.37M	-12.23M
Income Before Tax Ratio	-4,909.42%	-3,895.83%	-2,627.44%	-3,462.10%	-3,497.09%	-73.12%	0.00%	0.00%	0.00%	0.00%	0.00%
Income Tax Expense	-85.00K	-1.21M	105.00K	313.00K	-749.00K	-517.00K	-273.00K	17.00K	2.63M	1.41M	-244.00K
Net Income	-32.22M	-28.71M	-24.33M	-19.77M	-20.46M	-10.14M	-16.00M	-14.89M	-17.41M	-17.37M	-12.23M
Net Income Ratio	-4,896.50%	-3,738.02%	-2,638.83%	-3,517.79%	-3,497.09%	-73.12%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS	-0.42	-0.41	-0.56	-0.55	-0.62	-0.37	-0.64	-0.73	-3.09	-1.44	-1.01
EPS Diluted	-0.42	-0.41	-0.56	-0.55	-0.62	-0.37	-0.64	-0.73	-3.09	-1.44	-1.01
Weighted Avg Shares Out	77.55M	69.33M	43.67M	35.88M	32.97M	27.40M	24.97M	20.31M	5.63M	12.05M	12.05M
Weighted Avg Shares Out (Dil)	77.55M	69.33M	43.67M	35.88M	32.97M	27.40M	24.97M	20.31M	5.63M	12.05M	12.05M

VBL Therapeutics to Participate at March Investor Conferences

March 3, 2022globenewswire.com

TEL AVIV, Israel and NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that management will participate in a fireside...

VBL Therapeutics to Participate in the Guggenheim Oncology Conference and the 2022 BIO CEO & Investor Conference

February 2, 2022globenewswire.com

TEL AVIV, Israel and NEW YORK, Feb. 02, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a late-clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that Dror Harats, M.D.,...

VBL Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

January 6, 2022globenewswire.com

TEL AVIV, Israel and NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical stage biotechnology company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune-inflammatory indications, today announced that Dror Harats, M.D., Chief Executive...

What Makes Vascular Biogenics (VBLT) a New Buy Stock

November 18, 2021zacks.com

Vascular Biogenics (VBLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2021 Results - Earnings Call Transcript

November 15, 2021seekingalpha.com

Vascular Biogenics Ltd. (VBLT) CEO Dror Harats on Q3 2021 Results - Earnings Call Transcript

Vascular Biogenics (VBLT) Reports Q3 Loss, Lags Revenue Estimates

November 15, 2021zacks.com

Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 10.00% and -0.50%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

VBL Therapeutics to Report Third Quarter Financial Results on November 15

November 8, 2021globenewswire.com

TEL AVIV, Israel and NEW YORK, Nov. 08, 2021 (GLOBE NEWSWIRE) -- VB L Therape u tics (Nasdaq: VBLT ), a clinical stage company developing first-in-class therapeutics for difficult-to-treat malignant solid tumors and immune or inflammatory indications, today announced that...

VBL Therapeutics Announces Independent Data Safety Monitoring Committee Provides Clearance to Continue the OVAL Phase 3 Registration-Enabling Study of VB-111 in Ovarian Cancer

September 17, 2021globenewswire.com

TEL AVIV, Israel, Sept. 17, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced that the independent Data Safety Monitoring Committee (DSMC) of the ongoing OVAL Phase 3 registration-enabling study of VB-111 in ovarian cancer has conducted its fifth...

VBL Therapeutics to Present at Upcoming Conferences

September 10, 2021globenewswire.com

TEL AVIV, Israel, Sept. 10, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ: VBLT) today announced the Company will present in the following upcoming industry conferences: